Coexistence of KRAS mutation with mutant but not wild-type EGFR predicts response to tyrosine-kinase inhibitors in human lung cancer

被引：27
|
作者：
Choughule, A. [1 ]
Sharma, R. [1 ,2 ]
Trivedi, V. [1 ,2 ]
Thavamani, A. [1 ,2 ]
Noronha, V. [1 ]
Joshi, A. [1 ]
Desai, S. [3 ]
Chandrani, P. [2 ]
Sundaram, P. [2 ]
Utture, S. [1 ]
Jambhekar, N. [3 ]
Gupta, S. [1 ]
Aich, J. [2 ]
Prabhash, K. [1 ]
Dutt, A. [2 ]
机构：
[1] Tata Mem Hosp, Tata Mem Ctr, Dept Med Oncol, Bombay 400012, Maharashtra, India
[2] Tata Mem Hosp, Adv Ctr Treatment Res & Educ Canc, Navi Mumbai, India
[3] Tata Mem Hosp, Tata Mem Ctr, Dept Pathol, Bombay 400012, Maharashtra, India
来源：
BRITISH JOURNAL OF CANCER | 2014年 / 111卷 / 11期
基金：
英国惠康基金;
关键词：
GROWTH-FACTOR-RECEPTOR; GEFITINIB; THERAPY; GENE; ERLOTINIB; SURVIVAL; FEATURES;
D O I：
10.1038/bjc.2014.401
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：2203 / 2204
页数：4
相关论文
共 50 条
  • [1] Coexistence of KRAS mutation with mutant but not wild-type EGFR predicts response to tyrosine-kinase inhibitors in human lung cancer
    A Choughule
    R Sharma
    V Trivedi
    A Thavamani
    V Noronha
    A Joshi
    S Desai
    P Chandrani
    P Sundaram
    S Utture
    N Jambhekar
    S Gupta
    J Aich
    K Prabhash
    A Dutt
    British Journal of Cancer, 2014, 111 : 2203 - 2204
  • [2] KRAS and EGFR status as predictive markers of response and time to progression in EGFR wild-type stage IV non-small cell lung cancer (NSCLC) patients treated with EGFR tyrosine-kinase inhibitors.
    Domine, Manuel
    Rojo, Federico
    Hernandez, Tatiana
    Zazo, Sandra
    Serrano, Gloria
    Chamizo, Cristina
    Carames, Cristina
    Madoz, Juan
    Moreno, Irene
    Perez-Gonzalez, Nuria
    Ortega, Carolina
    Carvajal, Nerea
    Lobo, Francisco
    Laura Auz, Carmen
    Casado, Victoria
    Rubio, Gustavo
    Oruezabal, Mauro
    Lendinez, Alberto
    Leon, Ana
    Garcia-Foncillas, Jesus
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [3] The Use of EGFR Tyrosine Kinase Inhibitors in EGFR Wild-Type Non-Small-Cell Lung Cancer
    Thomas E. Stinchcombe
    Current Treatment Options in Oncology, 2016, 17
  • [4] The Use of EGFR Tyrosine Kinase Inhibitors in EGFR Wild-Type Non-Small-Cell Lung Cancer
    Stinchcombe, Thomas E.
    CURRENT TREATMENT OPTIONS IN ONCOLOGY, 2016, 17 (04)
  • [5] Effects of EGFR inhibition with tyrosine kinase inhibitors on invasive properties of EGFR mutant and wild type lung cancer cells
    Umelo, I. A.
    De Wever, O.
    Teugels, E.
    Bracke, M.
    De Greve, J.
    EJC SUPPLEMENTS, 2010, 8 (07): : 68 - 68
  • [6] KRAS, EGFR MUTATIONS AND EGFR GENE COPY STATUS AS PREDICTIVE MARKERS OF RESPONSE AND TIME TO PROGRESSION IN EGFR WILD-TYPE STAGE IV NON-SMALL CELL LUNG CANCER (NSCLC) PATIENTS TREATED WITH EGFR TYROSINE-KINASE INHIBITORS.
    Domine, Manuel
    Rojo, Federico
    Hernandez, Tatiana
    Zazo, Sandra
    Serrano, Gloria
    Chamizo, Cristina
    Carames, Cristina
    Madoz, Juan
    Moreno, Irene
    Perez Gonzalez, Nuria
    Ortega, Carolina
    Carvajal, Nerea
    Lobo, Francisco
    Laura Auz, Carmen
    Casado, Victoria
    Rubio, Gustavo
    Leon, Ana
    Martin Valades, Jose Ignacio
    Izarzugaza, Yann
    Luis Arranz, Juan
    Jesus Fernandez-Acenero, Maria
    Lendinez, Alberto
    Oruezabal, Mauro
    Martinez-Amores, Brezo
    Ramirez, Natalia
    Garcia Foncillas, Jesus
    JOURNAL OF THORACIC ONCOLOGY, 2013, 8 : S1094 - S1094
  • [7] Wild-type KRAS dosage in mutant KRAS lung cancer: Implications for tumorigenesis and therapeutic response
    Ivanisevic, Tonci
    Vande Velde, Greetje
    Zhao, Peihua
    Magits, Wout
    Sewduth, Raj N.
    Sablina, Anna A.
    CANCER RESEARCH, 2024, 84 (06)
  • [8] RAS signaling pathway gene mutations and acquired resistance to EGFR tyrosine-kinase inhibitors in EGFR mutant lung cancer
    Ohashi, Kadoaki
    Chmielecki, Juliann
    Lin, Ya-Lun
    Pan, Helen
    Vnencak-Jones, Cindy
    Arcila, Maria
    Wang, Lu
    Fernandez, Lynnette
    Keisuke, Aoe
    Shien, Kazuhiko
    Yamamoto, Hiromasa
    Toyooka, Shinichi
    Kiura, Katsuyuki
    Thomas, Roman
    Yang, James Chih-Hsin
    Miller, Vincent
    Ladanyi, Marc
    Politi, Katerina
    Pao, William
    CANCER RESEARCH, 2012, 72
  • [9] KRAS mutation is a predictor of poor response to EGFR tyrosine kinase inhibitors in NSCLC
    Nature Clinical Practice Oncology, 2007, 4 (9): : 503 - 504
  • [10] KRAS MUTATION IN EGFR WILD TYPE INDONESIAN LUNG CANCER PATIENT
    Masykura, Najmiatul
    Kharunisa, Bela Haifa
    Zaini, Jamal
    Andarini, Sita Laksmi
    Hudoyo, Achmad
    Syahruddin, Elisna
    Hidajat, Heriawaty
    Widjajahakim, Grace
    Utomo, Ahmad
    RESPIROLOGY, 2017, 22 : 73 - 73
12345